カテゴリ： QYResearch, 世界, 医療/バイオ

組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の世界市場2023年：バイアル、プレフィルド

■ 英語タイトル：Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA8882）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA8882
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：112
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の世界市場2023年：バイアル、プレフィルド]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

本調査資料は組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）のグローバル市場について調査・分析し、世界の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（バイアル、プレフィルド）、用途別セグメント分析（骨髄抑制化学療法、白血病化学療法、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Abbott、Amgen、Arven Pharmaceuticals、Biocon、Cadila Pharmaceuticals、Dr.Reddy's Laboratories、Emcure Pharmaceuticals、Intas Pharmaceuticals、Kyowa Kirin、Novartis、Pfizer、Reliance Life Sciences、Harbin Pharmaceutical、North China Pharmaceutical、Jiuyuan Gene、Kexing Biopharm、Qilu Pharmaceutical、Quangang Pharmaceutical、Sunway Biotech、SL Pharmaceutical、Four Rings Bio-Pharmaceutical、Amoytop、Wuzhong Pharmaceuticalなどが含まれています。組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）のグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。新型コロナとロシア・ウクライナ戦争の影響は、組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模を算出する際に考慮しました。

・組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場の概要
- 製品の定義
- 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の種類別セグメント
- 世界の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模：タイプ別分析（バイアル、プレフィルド）
- 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の用途別セグメント
- 世界の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模：用途別分析（骨髄抑制化学療法、白血病化学療法、その他）
- 世界の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模予測（2018年-2029年）
- 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の平均価格推移（2018年-2029年）
- 前提条件と制限事項

・メーカー別競争状況
- メーカー別市場シェア
- 世界の主要メーカー、業界ランキング分析
- メーカー別平均価格
- 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場の競争状況およびトレンド

・組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の地域別市場規模
- 北米の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模（2018年-2029年）
- 米国の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模（2018年-2029年）
- ヨーロッパの組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模（2018年-2029年）
- アジア太平洋の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模（2018年-2029年）
- 中国の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模（2018年-2029年）
- 日本の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模（2018年-2029年）
- 韓国の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模（2018年-2029年）
- インドの組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模（2018年-2029年）
- オーストラリアの組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模（2018年-2029年）
- 中南米の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模（2018年-2029年）
- 中東・アフリカの組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模（2018年-2029年）

・種類別セグメント：バイアル、プレフィルド
- 世界の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）のタイプ別販売量（2018年-2023年）
- 世界の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）のタイプ別売上（2018年-2023年）
- 世界の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）のタイプ別価格

・用途別セグメント：骨髄抑制化学療法、白血病化学療法、その他
- 世界の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の用途別販売量（2018年-2023年）
- 世界の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の用途別売上（2018年-2023年）
- 世界の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の用途別価格

・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向
Abbott、Amgen、Arven Pharmaceuticals、Biocon、Cadila Pharmaceuticals、Dr.Reddy's Laboratories、Emcure Pharmaceuticals、Intas Pharmaceuticals、Kyowa Kirin、Novartis、Pfizer、Reliance Life Sciences、Harbin Pharmaceutical、North China Pharmaceutical、Jiuyuan Gene、Kexing Biopharm、Qilu Pharmaceutical、Quangang Pharmaceutical、Sunway Biotech、SL Pharmaceutical、Four Rings Bio-Pharmaceutical、Amoytop、Wuzhong Pharmaceutical

・産業チェーンと販売チャネルの分析
- 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）産業チェーン分析
- 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の主要原材料
- 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の販売チャネル
- 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）のディストリビューター
- 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の主要顧客

・組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場ダイナミクス
- 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の業界動向
- 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場の成長ドライバ、課題、阻害要因

・調査の結論

・調査手法と情報源

Highlights
The global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) include Abbott, Amgen, Arven Pharmaceuticals, Biocon, Cadila Pharmaceuticals, Dr.Reddy’s Laboratories, Emcure Pharmaceuticals, Intas Pharmaceuticals and Kyowa Kirin, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF).
The Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market size, estimations, and forecasts are provided in terms of sales volume (K L) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Abbott
Amgen
Arven Pharmaceuticals
Biocon
Cadila Pharmaceuticals
Dr.Reddy’s Laboratories
Emcure Pharmaceuticals
Intas Pharmaceuticals
Kyowa Kirin
Novartis
Pfizer
Reliance Life Sciences
Harbin Pharmaceutical
North China Pharmaceutical
Jiuyuan Gene
Kexing Biopharm
Qilu Pharmaceutical
Quangang Pharmaceutical
Sunway Biotech
SL Pharmaceutical
Four Rings Bio-Pharmaceutical
Amoytop
Wuzhong Pharmaceutical
Segment by Type
Vials
Prefilled
Segment by Application
Myelosuppressive Chemotherapy
Leukemia Chemotherapy
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Overview
1.1 Product Overview and Scope of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF)
1.2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Segment by Type
1.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Value Comparison by Type (2023-2029)
1.2.2 Vials
1.2.3 Prefilled
1.3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Segment by Application
1.3.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Value by Application: (2023-2029)
1.3.2 Myelosuppressive Chemotherapy
1.3.3 Leukemia Chemotherapy
1.3.4 Others
1.4 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size Estimates and Forecasts
1.4.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue 2018-2029
1.4.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales 2018-2029
1.4.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Competition by Manufacturers
2.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Manufacturers (2018-2023)
2.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price by Manufacturers (2018-2023)
2.4 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF), Product Type & Application
2.7 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Competitive Situation and Trends
2.7.1 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Players Market Share by Revenue
2.7.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Retrospective Market Scenario by Region
3.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Region: 2018-2029
3.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Region: 2018-2023
3.2.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Region: 2024-2029
3.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Region: 2018-2029
3.3.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Region: 2018-2023
3.3.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Region: 2024-2029
3.4 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Facts & Figures by Country
3.4.1 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2018-2029)
3.4.3 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Facts & Figures by Country
3.5.1 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2018-2029)
3.5.3 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Facts & Figures by Country
3.6.1 Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2018-2029)
3.6.3 Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Facts & Figures by Country
3.7.1 Latin America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2018-2029)
3.7.3 Latin America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2018-2029)
3.8.3 Middle East and Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Type (2018-2029)
4.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Type (2018-2023)
4.1.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Type (2024-2029)
4.1.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Type (2018-2029)
4.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Type (2018-2029)
4.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Type (2018-2023)
4.2.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Type (2024-2029)
4.2.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Type (2018-2029)
4.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Price by Type (2018-2029)
5 Segment by Application
5.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Application (2018-2029)
5.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Application (2018-2023)
5.1.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Application (2024-2029)
5.1.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Application (2018-2029)
5.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Application (2018-2029)
5.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Application (2018-2023)
5.2.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Application (2024-2029)
5.2.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Application (2018-2029)
5.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Abbott
6.1.1 Abbott Corporation Information
6.1.2 Abbott Description and Business Overview
6.1.3 Abbott Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Abbott Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.1.5 Abbott Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Corporation Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Amgen Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 Arven Pharmaceuticals
6.3.1 Arven Pharmaceuticals Corporation Information
6.3.2 Arven Pharmaceuticals Description and Business Overview
6.3.3 Arven Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Arven Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.3.5 Arven Pharmaceuticals Recent Developments/Updates
6.4 Biocon
6.4.1 Biocon Corporation Information
6.4.2 Biocon Description and Business Overview
6.4.3 Biocon Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Biocon Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.4.5 Biocon Recent Developments/Updates
6.5 Cadila Pharmaceuticals
6.5.1 Cadila Pharmaceuticals Corporation Information
6.5.2 Cadila Pharmaceuticals Description and Business Overview
6.5.3 Cadila Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Cadila Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.5.5 Cadila Pharmaceuticals Recent Developments/Updates
6.6 Dr.Reddy’s Laboratories
6.6.1 Dr.Reddy’s Laboratories Corporation Information
6.6.2 Dr.Reddy’s Laboratories Description and Business Overview
6.6.3 Dr.Reddy’s Laboratories Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Dr.Reddy’s Laboratories Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.6.5 Dr.Reddy’s Laboratories Recent Developments/Updates
6.7 Emcure Pharmaceuticals
6.6.1 Emcure Pharmaceuticals Corporation Information
6.6.2 Emcure Pharmaceuticals Description and Business Overview
6.6.3 Emcure Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Emcure Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.7.5 Emcure Pharmaceuticals Recent Developments/Updates
6.8 Intas Pharmaceuticals
6.8.1 Intas Pharmaceuticals Corporation Information
6.8.2 Intas Pharmaceuticals Description and Business Overview
6.8.3 Intas Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Intas Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.8.5 Intas Pharmaceuticals Recent Developments/Updates
6.9 Kyowa Kirin
6.9.1 Kyowa Kirin Corporation Information
6.9.2 Kyowa Kirin Description and Business Overview
6.9.3 Kyowa Kirin Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Kyowa Kirin Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.9.5 Kyowa Kirin Recent Developments/Updates
6.10 Novartis
6.10.1 Novartis Corporation Information
6.10.2 Novartis Description and Business Overview
6.10.3 Novartis Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Novartis Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.10.5 Novartis Recent Developments/Updates
6.11 Pfizer
6.11.1 Pfizer Corporation Information
6.11.2 Pfizer Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.11.3 Pfizer Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Pfizer Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.11.5 Pfizer Recent Developments/Updates
6.12 Reliance Life Sciences
6.12.1 Reliance Life Sciences Corporation Information
6.12.2 Reliance Life Sciences Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.12.3 Reliance Life Sciences Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Reliance Life Sciences Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.12.5 Reliance Life Sciences Recent Developments/Updates
6.13 Harbin Pharmaceutical
6.13.1 Harbin Pharmaceutical Corporation Information
6.13.2 Harbin Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.13.3 Harbin Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Harbin Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.13.5 Harbin Pharmaceutical Recent Developments/Updates
6.14 North China Pharmaceutical
6.14.1 North China Pharmaceutical Corporation Information
6.14.2 North China Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.14.3 North China Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.14.4 North China Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.14.5 North China Pharmaceutical Recent Developments/Updates
6.15 Jiuyuan Gene
6.15.1 Jiuyuan Gene Corporation Information
6.15.2 Jiuyuan Gene Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.15.3 Jiuyuan Gene Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Jiuyuan Gene Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.15.5 Jiuyuan Gene Recent Developments/Updates
6.16 Kexing Biopharm
6.16.1 Kexing Biopharm Corporation Information
6.16.2 Kexing Biopharm Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.16.3 Kexing Biopharm Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Kexing Biopharm Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.16.5 Kexing Biopharm Recent Developments/Updates
6.17 Qilu Pharmaceutical
6.17.1 Qilu Pharmaceutical Corporation Information
6.17.2 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.17.3 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.17.5 Qilu Pharmaceutical Recent Developments/Updates
6.18 Quangang Pharmaceutical
6.18.1 Quangang Pharmaceutical Corporation Information
6.18.2 Quangang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.18.3 Quangang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Quangang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.18.5 Quangang Pharmaceutical Recent Developments/Updates
6.19 Sunway Biotech
6.19.1 Sunway Biotech Corporation Information
6.19.2 Sunway Biotech Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.19.3 Sunway Biotech Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Sunway Biotech Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.19.5 Sunway Biotech Recent Developments/Updates
6.20 SL Pharmaceutical
6.20.1 SL Pharmaceutical Corporation Information
6.20.2 SL Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.20.3 SL Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.20.4 SL Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.20.5 SL Pharmaceutical Recent Developments/Updates
6.21 Four Rings Bio-Pharmaceutical
6.21.1 Four Rings Bio-Pharmaceutical Corporation Information
6.21.2 Four Rings Bio-Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.21.3 Four Rings Bio-Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.21.4 Four Rings Bio-Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.21.5 Four Rings Bio-Pharmaceutical Recent Developments/Updates
6.22 Amoytop
6.22.1 Amoytop Corporation Information
6.22.2 Amoytop Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.22.3 Amoytop Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.22.4 Amoytop Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.22.5 Amoytop Recent Developments/Updates
6.23 Wuzhong Pharmaceutical
6.23.1 Wuzhong Pharmaceutical Corporation Information
6.23.2 Wuzhong Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.23.3 Wuzhong Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.23.4 Wuzhong Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.23.5 Wuzhong Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Industry Chain Analysis
7.2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Production Mode & Process
7.4 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales and Marketing
7.4.1 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Channels
7.4.2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Distributors
7.5 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Customers
8 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Dynamics
8.1 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Industry Trends
8.2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Drivers
8.3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Challenges
8.4 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Tables
Table 1. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Competitive Situation by Manufacturers in 2022
Table 4. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L) of Key Manufacturers (2018-2023)
Table 5. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price (US$/L) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF), Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF), Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF), Product Type & Application
Table 12. Global Key Manufacturers of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF), Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Region (2018-2023) & (K L)
Table 18. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Region (2018-2023)
Table 19. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Region (2024-2029) & (K L)
Table 20. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Region (2024-2029)
Table 21. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Region (2018-2023)
Table 23. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Region (2024-2029)
Table 25. North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2018-2023) & (K L)
Table 27. North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2024-2029) & (K L)
Table 28. North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2018-2023) & (K L)
Table 32. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2024-2029) & (K L)
Table 33. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Region (2018-2023) & (K L)
Table 37. Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Region (2024-2029) & (K L)
Table 38. Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2018-2023) & (K L)
Table 42. Latin America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2024-2029) & (K L)
Table 43. Latin America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2018-2023) & (K L)
Table 47. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2024-2029) & (K L)
Table 48. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L) by Type (2018-2023)
Table 51. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L) by Type (2024-2029)
Table 52. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Type (2018-2023)
Table 53. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Type (2024-2029)
Table 54. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Type (2018-2023)
Table 57. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Type (2024-2029)
Table 58. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Price (US$/L) by Type (2018-2023)
Table 59. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Price (US$/L) by Type (2024-2029)
Table 60. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L) by Application (2018-2023)
Table 61. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L) by Application (2024-2029)
Table 62. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Application (2018-2023)
Table 63. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Application (2024-2029)
Table 64. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Application (2018-2023)
Table 67. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Application (2024-2029)
Table 68. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Price (US$/L) by Application (2018-2023)
Table 69. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Price (US$/L) by Application (2024-2029)
Table 70. Abbott Corporation Information
Table 71. Abbott Description and Business Overview
Table 72. Abbott Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 73. Abbott Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 74. Abbott Recent Developments/Updates
Table 75. Amgen Corporation Information
Table 76. Amgen Description and Business Overview
Table 77. Amgen Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 78. Amgen Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 79. Amgen Recent Developments/Updates
Table 80. Arven Pharmaceuticals Corporation Information
Table 81. Arven Pharmaceuticals Description and Business Overview
Table 82. Arven Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 83. Arven Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 84. Arven Pharmaceuticals Recent Developments/Updates
Table 85. Biocon Corporation Information
Table 86. Biocon Description and Business Overview
Table 87. Biocon Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 88. Biocon Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 89. Biocon Recent Developments/Updates
Table 90. Cadila Pharmaceuticals Corporation Information
Table 91. Cadila Pharmaceuticals Description and Business Overview
Table 92. Cadila Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 93. Cadila Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 94. Cadila Pharmaceuticals Recent Developments/Updates
Table 95. Dr.Reddy's Laboratories Corporation Information
Table 96. Dr.Reddy's Laboratories Description and Business Overview
Table 97. Dr.Reddy's Laboratories Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 98. Dr.Reddy's Laboratories Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 99. Dr.Reddy's Laboratories Recent Developments/Updates
Table 100. Emcure Pharmaceuticals Corporation Information
Table 101. Emcure Pharmaceuticals Description and Business Overview
Table 102. Emcure Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 103. Emcure Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 104. Emcure Pharmaceuticals Recent Developments/Updates
Table 105. Intas Pharmaceuticals Corporation Information
Table 106. Intas Pharmaceuticals Description and Business Overview
Table 107. Intas Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 108. Intas Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 109. Intas Pharmaceuticals Recent Developments/Updates
Table 110. Kyowa Kirin Corporation Information
Table 111. Kyowa Kirin Description and Business Overview
Table 112. Kyowa Kirin Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 113. Kyowa Kirin Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 114. Kyowa Kirin Recent Developments/Updates
Table 115. Novartis Corporation Information
Table 116. Novartis Description and Business Overview
Table 117. Novartis Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 118. Novartis Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 119. Novartis Recent Developments/Updates
Table 120. Pfizer Corporation Information
Table 121. Pfizer Description and Business Overview
Table 122. Pfizer Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 123. Pfizer Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 124. Pfizer Recent Developments/Updates
Table 125. Reliance Life Sciences Corporation Information
Table 126. Reliance Life Sciences Description and Business Overview
Table 127. Reliance Life Sciences Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 128. Reliance Life Sciences Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 129. Reliance Life Sciences Recent Developments/Updates
Table 130. Harbin Pharmaceutical Corporation Information
Table 131. Harbin Pharmaceutical Description and Business Overview
Table 132. Harbin Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 133. Harbin Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 134. Harbin Pharmaceutical Recent Developments/Updates
Table 135. North China Pharmaceutical Corporation Information
Table 136. North China Pharmaceutical Description and Business Overview
Table 137. North China Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 138. North China Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 139. North China Pharmaceutical Recent Developments/Updates
Table 140. Jiuyuan Gene Corporation Information
Table 141. Jiuyuan Gene Description and Business Overview
Table 142. Jiuyuan Gene Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 143. Jiuyuan Gene Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 144. Jiuyuan Gene Recent Developments/Updates
Table 145. Kexing Biopharm Corporation Information
Table 146. Kexing Biopharm Description and Business Overview
Table 147. Kexing Biopharm Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 148. Kexing Biopharm Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 149. Kexing Biopharm Recent Developments/Updates
Table 150. Qilu Pharmaceutical Corporation Information
Table 151. Qilu Pharmaceutical Description and Business Overview
Table 152. Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 153. Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 154. Qilu Pharmaceutical Recent Developments/Updates
Table 155. Quangang Pharmaceutical Corporation Information
Table 156. Quangang Pharmaceutical Description and Business Overview
Table 157. Quangang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 158. Quangang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 159. Quangang Pharmaceutical Recent Developments/Updates
Table 160. Sunway Biotech Corporation Information
Table 161. Sunway Biotech Description and Business Overview
Table 162. Sunway Biotech Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 163. Sunway Biotech Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 164. Sunway Biotech Recent Developments/Updates
Table 165. SL Pharmaceutical Corporation Information
Table 166. SL Pharmaceutical Description and Business Overview
Table 167. SL Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 168. SL Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 169. SL Pharmaceutical Recent Developments/Updates
Table 170. Four Rings Bio-Pharmaceutical Corporation Information
Table 171. Four Rings Bio-Pharmaceutical Description and Business Overview
Table 172. Four Rings Bio-Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 173. Four Rings Bio-Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 174. Four Rings Bio-Pharmaceutical Recent Developments/Updates
Table 175. Amoytop Corporation Information
Table 176. Amoytop Description and Business Overview
Table 177. Amoytop Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 178. Amoytop Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 179. Amoytop Recent Developments/Updates
Table 180. Wuzhong Pharmaceutical Corporation Information
Table 181. Wuzhong Pharmaceutical Description and Business Overview
Table 182. Wuzhong Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (K L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2018-2023)
Table 183. Wuzhong Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product
Table 184. Wuzhong Pharmaceutical Recent Developments/Updates
Table 185. Key Raw Materials Lists
Table 186. Raw Materials Key Suppliers Lists
Table 187. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Distributors List
Table 188. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Customers List
Table 189. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Trends
Table 190. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Drivers
Table 191. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Challenges
Table 192. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Restraints
Table 193. Research Programs/Design for This Report
Table 194. Key Data Information from Secondary Sources
Table 195. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF)
Figure 2. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Share by Type in 2022 & 2029
Figure 4. Vials Product Picture
Figure 5. Prefilled Product Picture
Figure 6. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 7. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Share by Application in 2022 & 2029
Figure 8. Myelosuppressive Chemotherapy
Figure 9. Leukemia Chemotherapy
Figure 10. Others
Figure 11. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 12. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size (2018-2029) & (US$ Million)
Figure 13. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales (2018-2029) & (K L)
Figure 14. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price (US$/L) & (2018-2029)
Figure 15. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Report Years Considered
Figure 16. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Share by Manufacturers in 2022
Figure 17. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Share by Manufacturers in 2022
Figure 18. The Global 5 and 10 Largest Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Players: Market Share by Revenue in 2022
Figure 19. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 20. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 21. North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Country (2018-2029)
Figure 22. North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Country (2018-2029)
Figure 23. U.S. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 24. Canada Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Country (2018-2029)
Figure 26. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Country (2018-2029)
Figure 27. Germany Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. France Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. U.K. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Italy Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Russia Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Region (2018-2029)
Figure 33. Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Region (2018-2029)
Figure 34. China Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Japan Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. South Korea Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. India Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Australia Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Taiwan Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Indonesia Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Thailand Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Malaysia Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Philippines Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Latin America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Country (2018-2029)
Figure 45. Latin America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Country (2018-2029)
Figure 46. Mexico Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Brazil Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Argentina Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Country (2018-2029)
Figure 50. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Country (2018-2029)
Figure 51. Turkey Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Saudi Arabia Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. U.A.E Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Global Sales Market Share of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) by Type (2018-2029)
Figure 55. Global Revenue Market Share of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) by Type (2018-2029)
Figure 56. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Price (US$/L) by Type (2018-2029)
Figure 57. Global Sales Market Share of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) by Application (2018-2029)
Figure 58. Global Revenue Market Share of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) by Application (2018-2029)
Figure 59. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Price (US$/L) by Application (2018-2029)
Figure 60. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Value Chain
Figure 61. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • PEG-rhG-CSFの世界市場2023年：バイアル、プレフィルド
  • アダゲンのグローバル市場展望 2023年-2029年：プレフィルド、バイアル
  • ペガデマーゼウシのグローバル市場展望 2023年-2029年：プレフィルド、バイアル
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA8882 )"組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の世界市場2023年：バイアル、プレフィルド" (英文：Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。